<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4135"><DrugName>Pixykine</DrugName><DrugSynonyms><Name><Value>PIXY-321</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Pixykine</Value></Name><Name><Value>Milodistim</Value></Name><Name><Value>Plasmid Immunex yeast 321</Value></Name></DrugSynonyms><CompanyOriginator id="14131">Immunex Corp</CompanyOriginator><CompaniesSecondary><Company id="14112">Wyeth</Company><Company id="14131">Immunex Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4135" type="Drug"><TargetEntity id="178504" type="siDrug">Milodistim</TargetEntity></SourceEntity><SourceEntity id="14112" type="Company"><TargetEntity id="4295903346" type="organizationId">Wyeth LLC</TargetEntity></SourceEntity><SourceEntity id="14131" type="Company"><TargetEntity id="4295906770" type="organizationId">Immunex Corp</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity><SourceEntity id="680" type="ciIndication"><TargetEntity id="10024384" type="MEDDRA"/><TargetEntity id="D007970" type="MeSH"/><TargetEntity id="-1936173113" type="omicsDisease"/><TargetEntity id="1001" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="223" type="Action"><TargetEntity id="3385" type="Mechanism">IL-3 Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00878" type="ciTarget"><TargetEntity id="56981" type="siTarget">GM-CSF Receptor (GM-CSF-R)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00984" type="ciTarget"><TargetEntity id="56151" type="siTarget">IL-3 receptor</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="158">HIV infection</Indication><Indication id="680">Leukopenia</Indication></IndicationsSecondary><ActionsPrimary><Action id="410">GM-CSF receptor agonist</Action><Action id="223">IL-3 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="84">Protein fusion</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-01T09:36:47.000Z</LastModificationDate><ChangeDateLast>2017-07-13T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; was being developed by Immunex as a colony stimulating factor fusion protein designed to combine the effects of GM-CSF and interleukin-3 into a single molecule.&lt;/para&gt;&lt;para&gt;Development was discontinued following initial phase III data [&lt;ulink linkID="325919" linkType="reference"&gt;325919&lt;/ulink&gt;]. Results from a phase III trial with &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; using Leukine as a control, showed no significant difference between the two drugs. &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; has IL-3 agonist properties, as well as its GM-CSF actions, and it was therefore expected that it would prove more effective than Leukine at stimulating immune cell function [&lt;ulink linkID="190906" linkType="reference"&gt;190906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II clinical trials for the treatment of myelosuppression resulting from cancer chemotherapy had shown promising results, including reduction of neutropenia and cumulative thrombocytopenia. Immunex was conducting a study of the cost of platelet transfusions for cancer patients, an expense which may be offset against the cost of &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; treatment [&lt;ulink linkID="174608" linkType="reference"&gt;174608&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In phase I/II trials, &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; showed promising results with a reduction in neutropenia and cumulative thrombocytopenia in patients with malignant lymphoma [&lt;ulink linkID="308264" linkType="reference"&gt;308264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 24 patients undergoing chemotherapy for sarcomas, &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; significantly reduced neutropenia and cumulative thrombocytopenia, allowing delivery of multiple cycles of chemotherapy at full dose without major antibiotic or transfusion support.&lt;/para&gt;&lt;para&gt;There was concern that the use of &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; to reduce myelosuppression after high dose chemotherapy may stimulate the proliferation of malignant cells which have functional GM-CSF or IL-3 receptors on their surfaces. A study of this effect was carried out on tumor cells taken directly from patients with solid tumors and lymphomas. Results showed that it is unlikely for &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; to stimulate the growth of malignant cells in patients with lymphoma or cancers of the breast, lung and ovary [&lt;ulink linkID="203554" linkType="reference"&gt;203554&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A licence to Bristol-Myers Squibb was terminated in December 1993 following the change of ownership of Immunex. At that time over 500 patients had been treated with the product since clinical trials began in 1991 [&lt;ulink linkID="161692" linkType="reference"&gt;161692&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sandoz holds patents covering recombinant DNA technologies related to IL-3. &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; may infringe on Sandoz's patent and any other company with GM-CSF DNA patents [&lt;ulink linkID="174608" linkType="reference"&gt;174608&lt;/ulink&gt;]. Under a settlement agreement between Immunex, Hoechst Roussel and Behringwerke in July 1992, all Behringwerke's rights to &lt;ulink linkID="4135" linkType="Drug"&gt;Pixykine&lt;/ulink&gt; were assigned to Immunex [&lt;ulink linkID="167666" linkType="reference"&gt;167666&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="WO">World</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14131">Immunex Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="680">Leukopenia</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14112">Wyeth</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-05-26T00:00:00.000Z</StatusDate><Source id="325919" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14131">Immunex Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="680">Leukopenia</Indication><StatusDate>1994-12-31T00:00:00.000Z</StatusDate><Source id="174608" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>1994-11-01T00:00:00.000Z</StatusDate><Source id="168703" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14112">Wyeth</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00878"><Name>GM-CSF receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00984"><Name>IL-3 receptor</Name><SwissprotNumbers><Swissprot>P26954</Swissprot><Swissprot>P26955</Swissprot><Swissprot>P32927</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="120887" title="American Cyanamid to market Immunex's Pixykine outside the US and Canada        "/><Deal id="184089" title="PIXY-321 ex-NA and BMS oncology products in US"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>